A Randomized, Subject- and Investigator-Blind, Placebo and Active-Controlled Study to Assess the Abuse Potential of Lasmiditan
Phase of Trial: Phase I
Latest Information Update: 20 Nov 2019
Price : $35 *
At a glance
- Drugs Lasmiditan (Primary) ; Alprazolam
- Indications Migraine
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 20 Nov 2019 Results published in the Journal of Clinical Pharmacology
- 11 Dec 2017 Status changed from recruiting to completed.
- 20 Oct 2017 Planned End Date changed from 1 Feb 2018 to 1 Nov 2017.